Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03438032 · ClinicalTrials.gov registry record
Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD
A clinical trial of Systemic Sclerosis and Fibrosis Lung, sponsored by Northwestern University.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT03438032: Completed study of Systemic Sclerosis and Fibrosis Lung, sponsored by Northwestern University.
NCT03438032 is a study of Systemic Sclerosis and Fibrosis Lung that has completed, run by Northwestern University. The registered enrollment target is 10 participants, below the 279-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03438032, a study of Systemic Sclerosis and Fibrosis Lung, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Alveolar macrophages isolated from bronchoalveolar lavage (BAL) fluid from systemic sclerosis (SSc) patients with clinically significant lung fibrosis will be studied at baseline and at 6 months after enrollment to assess longitudinally the presence and persistence of an emergent, pro-fibrotic alveolar macrophage population, using single cell RNA-Seq technology to measure the individual transcriptome from each cell.
Primary Outcome
Change in alveolar macrophage transcriptome at 6 months, as measured by single cell RNA-sequencing
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Bronchoscopy with lavage
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-06-28 |
| Est. Completion | 2024-03-08 |
What the finished NCT03438032 record still lists
NCT03438032 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 279-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Systemic Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Bronchoscopy with lavage is the first listed.
NCT03438032 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03438032 about?
NCT03438032 is a clinical study titled "Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD". Alveolar macrophages isolated from bronchoalveolar lavage (BAL) fluid from systemic sclerosis (SSc) patients with clinically significant lung fibrosis will be studied at baseline and at 6 months after enrollment to assess longitudinally the presence and persistence of an emergent, pro-fibrotic alveo...
What is the current status of trial NCT03438032?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2018-06-28. Estimated completion is 2024-03-08.
What conditions does trial NCT03438032 study?
This clinical trial studies the following conditions: Systemic Sclerosis, Fibrosis Lung.
What interventions are being tested in trial NCT03438032?
The interventions under investigation include: Bronchoscopy with lavage (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03438032?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03438032 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03438032's enrollment target sits among peer trials
10 25th of 26 higher than 2 of 26 other Systemic Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
RECRUITING · NA
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
New Orleans Pulmonary Hypertension Biobank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI